- Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
- Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
- FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
- Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
- Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
- Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
- Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
- Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
- Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
- Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
More ▼
Key statistics
On Friday, Nexalin Technology Inc (NXL:NAQ) closed at 0.8992, 255.70% above the 52 week low of 0.2528 set on Feb 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.01 |
---|---|
High | 1.45 |
Low | 0.801 |
Bid | 0.8079 |
Offer | 0.83 |
Previous close | 1.38 |
Average volume | 1.32m |
---|---|
Shares outstanding | 7.44m |
Free float | 5.73m |
P/E (TTM) | -- |
Market cap | 6.69m USD |
EPS (TTM) | -0.6676 USD |
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.
More ▼